Ingen internetforbindelse — viser den gemte version af siden.

Novartis AG ADR

USUSD
← Til screeneren

Novartis AG ADR (SW:NOVN) — Drug Manufacturers - General. Antal børser, hvor selskabets aktier handles: 6. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.

Om virksomheden

Websted
novartis.com
Sektor
Healthcare · Drug Manufacturers - General
Hovedkontor
BASEL, Switzerland
Administrerende direktør
Dr. Vasant Narasimhan M.D.
Ansatte
75 267
Grundlagt
1996
Udestående aktier
1.91 mia. pr. 2025-12-31
Free float
1.86 mia.
Markedsværdi
276.48 mia. USD
Insidere
0.01%
Institutionelle investorer
7.27%
Branche (SIC)
Pharmaceutical Preparations
Juridisk form
MVII
ISIN
CH0012005267
LEI
5493007HIVTX6SY6XD66
Udbetalingsgrad
71.1%
FCF
15.0 mia. USD
61%
Gæld
49.0 mia. USD
2.6 år FCF
Udbyttestreak
20 år
Beskrivelse

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Børser og tickere

BørsTickerValutaPrisType
US USA StocksNVSEFUSD134.22 -0.23%almindelige aktier
MI Borsa Italiana (Milan)1NOVNEUR127.6 +1.75%almindelige aktier
SW SIX Swiss ExchangeNOVNCHF119.8 -0.13%almindelige aktier
SW SIX Swiss ExchangeNOVNEECHF120.02 -1.80%almindelige aktier
VI Vienna Stock ExchangeNOVNEUR126.72almindelige aktier
XETRA XetraNOTEUR126.82 +0.48%almindelige aktier

Kurs over 3 måneder

stigningsdag faldsdag udbyttets ex-dato udbetalingsdatoHold musen over / tryk på en dag — åbnings-, luknings-, højeste og laveste kurs

Udbytte

De sidste 12 måneder, SW:NOVN: 3.7 CHF (1 udb.)

Novartis AG ADR (NOVN) udbetaler udbytte uregelmæssigt. I løbet af de sidste 12 måneder blev der betalt 3.7 CHF pr. Aktie (betalinger: 1). Det svarer til cirka 3.09% af den nuværende aktiekurs. Baseret på betalingshistorikken forventes næste ex-udbyttedato omkring 15.03.2027. Uafbrudt udbyttehistorik: 20 år.

Ex-datoUdbetalingBeløb%TypeTicker
2026-03-10—3.7000 CHF3.1/6.0 %årligSW:NOVN
2025-03-11—3.5000 CHF2.9/2.9 %årligSW:NOVN
2024-03-07—3.3000 CHF2.8/5.4 %årligSW:NOVN
2023-03-09—3.2000 CHF2.7/2.7 %årligSW:NOVN
2022-03-08—3.1000 CHF2.6/2.6 %årligSW:NOVN

Nyheder denne uge

Endnu ingen nyheder fra virksomhedens websted.

annonce

Største ejere

EjerAndelAktierRapportdato
Fisher Asset Management,…0.76%15.52 mio.2026-06-30
Morgan Stanley0.43%8.73 mio.2026-06-30
Dimensional Fund Advisor…0.4%8.12 mio.2026-06-30
Primecap Management Comp…0.32%6.59 mio.2026-06-30
LOOMIS SAYLES & CO L P0.26%5.24 mio.2026-06-30
Bank of America Corporat…0.24%4.91 mio.2026-06-30
VANGUARD CHESTER FUNDS-V…0.21%4.25 mio.2026-06-30
Franklin Resources, Inc.0.16%3.25 mio.2026-06-30
Blackrock Inc.0.15%3.05 mio.2026-06-30
Goldman Sachs Group Inc0.15%2.98 mio.2026-06-30
Northern Trust Corporati…0.14%2.79 mio.2026-06-30
DFA INVESTMENT DIMENSION…0.11%2.14 mio.2026-04-30
LOOMIS SAYLES FUNDS II-L…0.07%1.42 mio.2026-06-30
VANGUARD HORIZON FUNDS-V…0.06%1.21 mio.2026-06-30
Franklin Mutual Series F…0.06%1.19 mio.2026-06-30
JANUS INVESTMENT FUND-Ja…0.05%949 7262026-06-30
Principal Funds, Inc-Equ…0.05%945 0912026-04-30
Dimensional ETF Trust-Di…0.04%888 8552026-04-30
Franklin Mutual Series F…0.04%812 6182026-06-30
Dimensional ETF Trust-Di…0.04%716 8362026-04-30